The Neutrophil-to-Lymphocyte Ratio during Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Long-Term Therapeutic Efficacy: A Multicenter Analysis
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: Atezolizumab plus bevacizumab (ATZ/BEV) is used for the treatment of unresectable hepatocellular carcinoma (u-HCC). However, there are few reports investigating the predictors of whether or not disease control can be achieved for long periods. METHODS: We enrolled 106 u-HCC patients who were treated with ATZ/BEV as the first-line systemic chemotherapy and were evaluated as nonprogressive disease (non-PD) in their initial assessments. They were divided into two groups: patients who had achieved disease control (non-PD) for more than 6 months, Group-L, and patients who had progressed (PD) within 6 months, Group-S. We investigated the predictors of long-term therapeutic efficacy. RESULTS: Patients in Group-L had significantly lower neutrophil-to-lymphocyte ratios (NLR) (the ratios of NLR at the start of the second course of ATZ/BEV to their pretreatment levels) than Group-S (p = 0.044), and the optimal cutoff value was 1.129. The patients with an NLR ratio <1.129 had longer progression-free survival (PFS) and overall survival (OS) than those with an NLR ratio ≥1.129 (median: 16 vs. 6 months, p = 0.016 for PFS; not reached vs. 22 months, p = 0.007 for OS). Univariate and multivariate analyses showed that an NLR ratio ≥1.129 was an independent predictor for unfavorable PFS and OS (hazard ratio [HR] 2.03, p = 0.022 for PFS; HR 2.37, p = 0.019 for OS). CONCLUSIONS: In u-HCC patients treated with ATZ/BEV, a lower NLR ratio was associated with a durable response, which led to favorable PFS and OS.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The Neutrophil-to-Lymphocyte Ratio during Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Long-Term Therapeutic Efficacy: A Multicenter Analysis
- Date Crossref
- 07/07/2025
- Éditeur
- S. Karger AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Nagoya City University Department of Gastroenterology pays non établi dans la noticeUniversité ou école supérieure
-
Nagoya Medical Center pays non établi dans la noticeÉtablissement de santé
-
Japanese Red Cross Nagoya Daini Hospital pays non établi dans la noticeÉtablissement de santé
-
Gifu Prefectural Tajimi Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Kasugai Municipal Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Chukyo Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Toyokawa City Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Nagasaki Rousai Hospital pays non établi dans la noticeÉtablissement de santé
-
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Asahi Rousai Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
Department of Gastroenterology — Nagoya City University, Nagoya Medical Center et Japanese Red Cross Nagoya Daini Hospital, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.